The Administrative Core will be responsible for the overall management of this HIVRAD P01 program according to PAR 06-285.
Specific Aim 1 To coordinate overall interactions a) among scientists from the different institutions that are included in the current program and b) between our team and NIH personnel regarding efficient implementation of proposed research plans;
Specific Aim 2 To establish and implement milestones for the entire HIVRAD program and each project/core, and to prioritize and coordinate studies to be conducted by subcontractors;
Specific Aim 3 To oversee all budgetary matters, including the review and funding of studies to be conducted by subcontractors, to monitor regular expenses and to prepare for various financial reports;
Specific Aim 4 Information management: to provide bioinformatics and statistical support, to develop an Intellectual Property plan as needed, and to promote data standardization, and data and resource sharing.

Public Health Relevance

Core B (Administrative Core) will be responsible for the daily operation of this NIH funded HIV Vaccine Research and Development (HIVRAD) Program and will coordinate activitiesto be conducted by individual projects and cores.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-EC-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
United States
Zip Code
Suschak, John J; Wang, Shixia; Fitzgerald, Katherine A et al. (2015) Identification of Aim2 as a sensor for DNA vaccines. J Immunol 194:630-6
Pouliot, Kimberly; Buglione-Corbett, Rachel; Marty-Roix, Robyn et al. (2014) Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine 32:5049-56
Chen, Yuxin; Vaine, Michael; Wallace, Aaron et al. (2013) A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol 87:10232-43
Buglione-Corbett, Rachel; Pouliot, Kimberly; Marty-Roix, Robyn et al. (2013) Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One 8:e74820
Pan, Ruimin; Sampson, Jared M; Chen, Yuxin et al. (2013) Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans. J Virol 87:10221-31
Murphy, Megan K; Yue, Ling; Pan, Ruimin et al. (2013) Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9:e1003173
O'Connell, Olivia; Repik, Alexander; Reeves, Jacqueline D et al. (2013) Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J Virol 87:187-98
Peters, Paul J; Richards, Kathryn; Clapham, Paul (2013) Human immunodeficiency viruses: propagation, quantification, and storage. Curr Protoc Microbiol Chapter 15:Unit 15J.1
Gonzalez-Perez, Maria Paz; O'Connell, Olivia; Lin, Rongheng et al. (2012) Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue. Retrovirology 9:20
Duenas-Decamp, Maria J; O'Connell, Olivia J; Corti, Davide et al. (2012) The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies. Retrovirology 9:9

Showing the most recent 10 out of 22 publications